The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis

Blood Reviews

Volumn 27, Issue 3, 2013, Pages 119-132

  Winckers, Kristien ^a   Ten Cate, Hugo ^a   Hackeng, Tilman M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Anticoagulant; Atherosclerosis; Atherothrombosis; TFPI

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOGENESIS; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTERY THROMBOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GENETIC ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION;

ANIMALS; ANTICOAGULANTS; ATHEROSCLEROSIS; HUMANS; SIGNAL TRANSDUCTION; THROMBOPLASTIN; THROMBOSIS;

EID: 84877128538     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.03.001     Document Type: Article

References (155)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Wilcox J.N., Smith K.M., Schwartz S.M., Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989, 86:2839-2843.
3. Ardissino D., Merlini P.A., Ariens R., Coppola R., Bramucci E., Mannucci P.M. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997, 349:769-771.
4. Falciani M., Gori A.M., Fedi S., et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998, 79:495-499.
5. Morange P.E., Blankenberg S., Alessi M.C., et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007, 5:475-482.
6. Soejima H., Ogawa H., Yasue H., et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999, 99:2908-2913.
7. Ross R., Glomset J., Harker L. Response to injury and atherogenesis. Am J Pathol 1977, 86:675-684.
8. Galkina E., Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:2292-2301.
9. Sluimer J.C., Daemen M.J. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol 2009, 218:7-29.
10. Glagov S., Weisenberg E., Zarins C.K., Stankunavicius R., Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987, 316:1371-1375.
11. Bach R.R. Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 1988, 23:339-368.
12. Pawashe A.B., Golino P., Ambrosio G., et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994, 74:56-63.
13. Marmur J.D., Thiruvikraman S.V., Fyfe B.S., et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996, 94:1226-1232.
14. Owens A.P., Mackman N. Tissue factor and thrombosis: the clot starts here. Thromb Haemost 2010, 104:432-439.
15. Yamashita A., Matsuda S., Matsumoto T., et al. Thrombin generation by intimal tissue factor contributes to thrombus formation on macrophage-rich neointima but not normal intima of hyperlipidemic rabbits. Atherosclerosis 2009, 206:418-426.
16. Kaikita K., Ogawa H., Yasue H., et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol 1997, 17:2232-2237.
17. Sato Y., Asada Y., Marutsuka K., Hatakeyama K., Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996, 75:389-392.
18. Borissoff J.I., Spronk H.M., ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011, 364:1746-1760.
19. ten Cate H. Tissue factor-driven thrombin generation and inflammation in atherosclerosis. Thromb Res 2012, 129(Suppl. 2):S38-S40.
20. Tilley R.E., Pedersen B., Pawlinski R., et al. Atherosclerosis in mice is not affected by a reduction in tissue factor expression. Arterioscler Thromb Vasc Biol 2006, 26:555-562.
21. Kramer M.C., van der Wal A.C., Koch K.T., et al. Presence of older thrombus is an independent predictor of long-term mortality in patients with ST-elevation myocardial infarction treated with thrombus aspiration during primary percutaneous coronary intervention. Circulation 2008, 118:1810-1816.
22. Taubman M.B., Giesen P.L., Schecter A.D., Nemerson Y. Regulation of the procoagulant response to arterial injury. Thromb Haemost 1999, 82:801-805.
23. Gasic G.P., Arenas C.P., Gasic T.B., Gasic G.J. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci U S A 1992, 89:2317-2320.
24. Borissoff J.I., Spronk H.M., Heeneman S., ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis' maze?. Cardiovasc Res 2009, 82:392-403.
25. Chen L.B., Buchanan J.M. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci U S A 1975, 72:131-135.
26. Ross R., Glomset J., Kariya B., Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 1974, 71:1207-1210.
27. Jawien A., Bowen-Pope D.F., Lindner V., Schwartz S.M., Clowes A.W. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992, 89:507-511.
28. Borissoff J.I., Heeneman S., Kilinc E., et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010, 122:821-830.
29. Ragosta M., Gimple L.W., Gertz S.D., et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1994, 89:1262-1271.
30. Sarembock I.J., Gertz S.D., Gimple L.W., Owen R.M., Powers E.R., Roberts W.C. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991, 84:232-243.
31. Loeffen R., Spronk H.M., Ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost 2012, 10:1207-1216.
32. Broze G.J., Lange G.W., Duffin K.L., MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994, 5:551-559.
33. Wun T.C., Kretzmer K.K., Girard T.J., Miletich J.P., Broze G.J. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988, 263:6001-6004.
34. Broze G.J., Warren L.A., Novotny W.F., Higuchi D.A., Girard J.J., Miletich J.P. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988, 71:335-343.
35. Girard T.J., Warren L.A., Novotny W.F., et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989, 338:518-520.
36. Hackeng T.M., Sere K.M., Tans G., Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A 2006, 103:3106-3111.
37. Ndonwi M., Tuley E.A., Broze G.J. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 2010, 116:1344-1351.
38. Warshawsky I., Bu G., Mast A., Saffitz J.E., Broze G.J., Schwartz A.L. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995, 95:1773-1781.
39. Maroney S.A., Ellery P.E., Mast A.E. Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb Res 2010, 125(Suppl. 1):S52-S56.
40. Broze G.J., Girard T.J. Tissue factor pathway inhibitor: structure-function. Front Biosci 2012, 17:262-280.
41. Caplice N.M., Mueske C.S., Kleppe L.S., Peterson T.E., Broze G.J., Simari R.D. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res 1998, 83:1264-1270.
42. Maroney S.A., Mast A.E. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci 2008, 38:9-14.
43. McGee M.P., Foster S., Wang X. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. J Exp Med 1994, 179:1847-1854.
44. Werling R.W., Zacharski L.R., Kisiel W., Bajaj S.P., Memoli V.A., Rousseau S.M. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993, 69:366-369.
45. Petit L., Lesnik P., Dachet C., Moreau M., Chapman M.J. Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages: relationship to tissue factor induction by cholesterol and oxidized LDL. Arterioscler Thromb Vasc Biol 1999, 19:309-315.
46. Lupu C., Lupu F., Dennehy U., Kakkar V.V., Scully M.F. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1995, 15:2055-2062.
47. Lupu C., Poulsen E., Roquefeuil S., Westmuckett A.D., Kakkar V.V., Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999, 19:2251-2262.
48. Novotny W.F., Palmier M., Wun T.C., Broze G.J., Miletich J.P. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991, 78:394-400.
49. Sandset P.M., Abildgaard U., Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988, 50:803-813.
50. Lwaleed B.A., Bass P.S. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006, 208:327-339.
51. Novotny W.F., Girard T.J., Miletich J.P., Broze G.J. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988, 72:2020-2025.
52. Maroney S.A., Haberichter S.L., Friese P., et al. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 2007, 109:1931-1937.
53. Baugh R.J., Broze G.J., Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998, 273:4378-4386.
54. Wesselschmidt R., Likert K., Girard T., Wun T.C., Broze G.J. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992, 79:2004-2010.
55. Han X., Girard T.J., Baum P., Abendschein D.R., Broze G.J. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterioscler Thromb Vasc Biol 1999, 19:2563-2567.
56. Huang Z.F., Higuchi D., Lasky N., Broze G.J. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997, 90:944-951.
57. Chan J.C., Carmeliet P., Moons L., et al. Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. J Clin Invest 1999, 103:475-482.
58. Mitchell C.T., Kamineni A., Palmas W., Cushman M. Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2009, 207:277-283.
59. Tchaikovski S.N., Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010, 126:5-11.
60. Ariens R.A., Alberio G., Moia M., Mannucci P.M. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost 1999, 81:203-207.
61. Dahm A., Van Hylckama Vlieg A., Bendz B., Rosendaal F., Bertina R.M., Sandset P.M. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003, 101:4387-4392.
62. Maroney S.A., Cooley B.C., Ferrel J.P., et al. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci U S A 2012, 109:3927-3931.
63. Kasthuri R.S., Glover S.L., Boles J., Mackman N. Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays. Semin Thromb Hemost 2010, 36:764-771.
64. Maurissen L.F., Castoldi E., Simioni P., Rosing J., Hackeng T.M. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost 2010, 8:750-758.
65. Soejima H., Ogawa H., Yasue H., et al. Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. Thromb Res 1999, 93:17-25.
66. Crawley J., Lupu F., Westmuckett A.D., Severs N.J., Kakkar V.V., Lupu C. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000, 20:1362-1373.
67. Hatakeyama K., Asada Y., Marutsuka K., Kataoka H., Sato Y., Sumiyoshi A. Expression of tissue factor in the rabbit aorta after balloon injury. Atherosclerosis 1998, 139:265-271.
68. Marmur J.D., Rossikhina M., Guha A., et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993, 91:2253-2259.
69. Kaikita K., Takeya M., Ogawa H., Suefuji H., Yasue H., Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999, 188:180-188.
70. Holroyd E.W., Simari R.D. Interdependent biological systems, multi-functional molecules: the evolving role of tissue factor pathway inhibitor beyond anti-coagulation. Thromb Res 2010, 125(Suppl. 1):S57-S59.
71. Ragni M., Golino P., Cirillo P., et al. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury. Circulation 2000, 102:113-117.
72. Westrick R.J., Bodary P.F., Xu Z., Shen Y.C., Broze G.J., Eitzman D.T. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 2001, 103:3044-3046.
73. Roque M., Reis E.D., Fuster V., et al. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J Am Coll Cardiol 2000, 36:2303-2310.
74. St Pierre J., Yang L.Y., Tamirisa K., et al. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler Thromb Vasc Biol 1999, 19:2263-2268.
75. Kopp C.W., Holzenbein T., Steiner S., et al. Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity. Blood 2004, 103:1653-1661.
76. Nishida T., Ueno H., Atsuchi N., et al. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit. Circ Res 1999, 84:1446-1452.
77. Zoldhelyi P., McNatt J., Shelat H.S., Yamamoto Y., Chen Z.Q., Willerson J.T. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 2000, 101:289-295.
78. Sato Y., Kataoka H., Asada Y., et al. Overexpression of tissue factor pathway inhibitor in aortic smooth muscle cells inhibits cell migration induced by tissue factor/factor VIIa complex. Thromb Res 1999, 94:401-406.
79. Sato Y., Asada Y., Marutsuka K., Hatakeyama K., Kamikubo Y., Sumiyoshi A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Haemost 1997, 78:1138-1141.
80. Oltrona L., Speidel C.M., Recchia D., Wickline S.A., Eisenberg P.R., Abendschein D.R. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997, 96:646-652.
81. Jang Y., Guzman L.A., Lincoff A.M., et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995, 92:3041-3050.
82. Asada Y., Hara S., Tsuneyoshi A., et al. Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb Haemost 1998, 80:506-511.
83. Sun L.B., Utoh J., Moriyama S., Tagami H., Okamoto K., Kitamura N. Topically applied tissue factor pathway inhibitor reduced intimal thickness of small arterial autografts in rabbits. J Vasc Surg 2001, 34:151-155.
84. Atsuchi N., Nishida T., Marutsuka K., et al. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation 2001, 103:570-575.
85. Zoldhelyi P., Chen Z.Q., Shelat H.S., McNatt J.M., Willerson J.T. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci U S A 2001, 98:4078-4083.
86. Hembrough T.A., Ruiz J.F., Papathanassiu A.E., Green S.J., Strickland D.K. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 2001, 276:12241-12248.
87. Pan S., White T.A., Witt T.A., Chiriac A., Mueske C.S., Simari R.D. Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development. Circ Res 2009, 105:713-720. (718 pp. following 720).
88. Ohkura N., Enjyoji K., Kamikubo Y., Kato H. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood 1997, 90:1883-1892.
89. Li A., Wun T.C. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Thromb Haemost 1998, 80:423-427.
90. Salemink I., Franssen J., Willems G.M., et al. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Thromb Haemost 1998, 80:273-280.
91. Schuepbach R.A., Velez K., Riewald M. Activated protein C up-regulates procoagulant tissue factor activity on endothelial cells by shedding the TFPI Kunitz 1 domain. Blood 2011, 117:6338-6346.
92. Belaaouaj A.A., Li A., Wun T.C., Welgus H.G., Shapiro S.D. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem. 2000, 275:27123-27128.
93. Cunningham A.C., Hasty K.A., Enghild J.J., Mast A.E. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Biochem J 2002, 367:451-458.
94. Hamuro T., Kido H., Asada Y., et al. Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis. FEBS J 2007, 274:3065-3077.
95. Kanse S.M., Declerck P.J., Ruf W., Broze G., Etscheid M. Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2012, 32:427-433.
96. Petersen L.C., Bjorn S.E., Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1992, 67:537-541.
97. Drew A.F., Davenport P., Apostolopoulos J., Tipping P.G. Tissue factor pathway inhibitor expression in atherosclerosis. Lab Invest 1997, 77:291-298.
98. Ameri A., Kuppuswamy M.N., Basu S., Bajaj S.P. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992, 79:3219-3226.
99. Caplice N.M., Mueske C.S., Kleppe L.S., Simari R.D. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998, 98:1051-1057.
100. Novo G., Caplice N., Tantillo R., Bonura F., Simari R., Novo S. TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications. Int Angiol 2005, 24:366-371.
101. Sakkinen P.A., Cushman M., Psaty B.M., et al. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost 1998, 80:134-139.
102. Sakata T., Mannami T., Baba S., et al. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries. Atherosclerosis 2004, 176:355-360.
103. Baldassarre D., Porta B., Camera M., et al. Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis 2009, 19:481-490.
104. Porta B., Baldassarre D., Camera M., et al. E-selectin and TFPI are associated with carotid intima-media thickness in stable IHD patients: the baseline findings of the MIAMI study. Nutr Metab Cardiovasc Dis 2008, 18:320-328.
105. Al-Nozha M.M., Abdel-Gader A.G., Arafah M.R., et al. Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes. Saudi Med J 2005, 26:937-942.
106. Brodin E., Borvik T., Sandset P.M., Bonaa K.H., Nordoy A., Hansen J.B. Coagulation activation in young survivors of myocardial infarction (MI)-a population-based case-control study. Thromb Haemost 2004, 92:178-184.
107. Freeburn J.C., Wallace J.M., Strain J.J., et al. Monocyte tissue factor-like activity in post myocardial infarction patients. Br J Haematol 1998, 102:605-608.
108. He M., Wen Z., He X., et al. Observation on tissue factor pathway and some other coagulation parameters during the onset of acute cerebrocardiac thrombotic diseases. Thromb Res 2002, 107:223-228.
109. Kamikura Y., Wada H., Yamada A., et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 1997, 55:183-187.
110. Kawaguchi A., Miyao Y., Noguchi T., et al. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. Arterioscler Thromb Vasc Biol 2000, 20:251-258.
111. Moor E., Hamsten A., Karpe F., Bavenholm P., Blomback M., Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost 1994, 71:707-712.
112. Morange P.E., Simon C., Alessi M.C., et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004, 109:1343-1348.
113. Saigo M., Abe S., Ogawa M., et al. Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost 2001, 86:1197-1203.
114. Winckers K., Siegerink B., Duckers C., et al. Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study. J Thromb Haemost 2011, 9:2243-2250.
115. Sandset P.M., Sirnes P.A., Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 1989, 72:391-396.
116. Castoldi E., Simioni P., Tormene D., Rosing J., Hackeng T.M. Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost 2010, 8:294-300.
117. Golino P., Ravera A., Ragni M., Cirillo P., Piro O., Chiariello M. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation 2003, 108:2864-2869.
118. Figueras J., Monasterio J., Lidon R.M., Sambola A., Garcia-Dorado D. Lower tissue factor inhibition in patients with ST segment elevation than in patients with non ST elevation acute myocardial infarction. Thromb Res 2012.
119. Gissel M., Undas A., Slowik A., Mann K.G., Brummel-Ziedins K.E. Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events. Thromb Res 2010, 126:262-269.
120. Abumiya T., Yamaguchi T., Terasaki T., Kokawa T., Kario K., Kato H. Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb Haemost 1995, 74:1050-1054.
121. Adams M.J., Thom J., Hankey G.J., et al. The tissue factor pathway in ischemic stroke. Blood Coagul Fibrinolysis 2006, 17:527-532.
122. Rossouw J.E., Johnson K.C., Pettinger M., et al. Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy. Stroke 2012, 43:952-957.
123. Hassan A., Hunt B.J., O'Sullivan M., et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003, 126:424-432.
124. Knottnerus I.L., Winckers K., Ten Cate H., et al. Levels of heparin-releasable TFPI are increased in first-ever lacunar stroke patients. Neurology 2012, 78:493-498.
125. Markus H.S., Hunt B., Palmer K., Enzinger C., Schmidt H., Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005, 36:1410-1414.
126. Blann A.D., Amiral J., McCollum C.N., Lip G.Y. Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls. Atherosclerosis 2000, 152:29-34.
127. Gosk-Bierska I., Wysokin Ski W., Karnicki K., Adamiec R. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study. Int Angiol 2008, 27:296-301.
128. van der Logt C.P., Reitsma P.H., Bertina R.M. Intron-exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor: the factor Xa dependent inhibitor of the extrinsic pathway of coagulation. Biochemistry 1991, 30:1571-1577.
129. Almasy L., Soria J.M., Souto J.C., et al. A locus on chromosome 2 influences levels of tissue factor pathway inhibitor: results from the GAIT study. Arterioscler Thromb Vasc Biol 2005, 25:1489-1492.
130. Skretting G., Stavik B., Landvik N.E., et al. Functional characterization of polymorphisms in the human TFPI gene. Biochem Biophys Res Commun 2010, 397:106-111.
131. Moatti D., Haidar B., Fumeron F., et al. A new T-287C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haemost 2000, 84:244-249.
132. Moatti D., Meirhaeghe A., Ollivier V., Bauters C., Amouyel P., de Prost D. Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty. Blood Coagul Fibrinolysis 2001, 12:317-323.
133. Moatti D., Seknadji P., Galand C., et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol 1999, 19:862-869.
134. Sayer M.S., Cole V.J., Adams M.J., Baker R.I., Staton J.M. Polymorphisms in the tissue factor pathway inhibitor gene are not associated with ischaemic stroke. Blood Coagul Fibrinolysis 2007, 18:703-708.
135. Hubbard A.R., Jennings C.A. Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. Thromb Res 1987, 46:527-537.
136. Sandset P.M., Larsen M.L., Abildgaard U., Lindahl A.K., Odegaard O.R. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991, 2:425-433.
137. Novotny W.F., Brown S.G., Miletich J.P., Rader D.J., Broze G.J. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991, 78:387-393.
138. Hansen J.B., Huseby N.E., Sandset P.M., Svensson B., Lyngmo V., Nordoy A. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994, 14:223-229.
139. Sandset P.M., Lund H., Norseth J., Abildgaard U., Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 1991, 11:138-145.
140. Abumiya T., Nakamura S., Takenaka A., et al. Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys. Arterioscler Thromb 1994, 14:483-488.
141. Zawadzki C., Susen S., Richard F., et al. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins. Atherosclerosis 2007, 195:e117-e125.
142. Owens A.P., Passam F.H., Antoniak S., et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012, 122:558-568.
143. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23:168-175.
144. Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007, 115:1285-1295.
145. Furomoto T., Fujii S., Saito N., Mikami T., Kitabatake A. Relationships between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J 2002, 43:117-125.
146. Regnault V., Perret-Guillaume C., Kearney-Schwartz A., et al. Tissue factor pathway inhibitor: a new link among arterial stiffness, pulse pressure, and coagulation in postmenopausal women. Arterioscler Thromb Vasc Biol 2011, 31:1226-1232.
147. Makris T.K., Stavroulakis G., Papadopoulos D.P., et al. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. Drugs Exp Clin Res 2004, 30:125-132.
148. Makris T.K., Stavroulakis G.A., Krespi P.G., et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000, 13:783-788.
149. Fitzgerald D.J., Roy L., Catella F., FitzGerald G.A. Platelet activation in unstable coronary disease. N Engl J Med 1986, 315:983-989.
150. Suefuji H., Ogawa H., Yasue H., et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997, 134:253-259.
151. Misumi K., Ogawa H., Yasue H., et al. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998, 81:22-26.
152. Sebestjen M., Zegura B., Videcnik V., Keber I. Determinants of endothelial dysfunction and carotid intima-media thickness in combined hyperlipidemia. Coron Artery Dis 2005, 16:175-180.
153. Sere K.M., Hackeng T.M. Basic mechanisms of hemostasis. Semin Vasc Med 2003, 3:3-12.
154. Choudhury R.P., Fuster V., Fayad Z.A. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 2004, 3:913-925.
155. Mast A.E., Stadanlick J.E., Lockett J.M., Dietzen D.J., Hasty K.A., Hall C.L. Tissue factor pathway inhibitor binds to platelet thrombospondin-1. J Biol Chem 2000, 275:31715-31721.